Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

about

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

Item

http://www.wikidata.org/entity/Q56889672

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Neurologic immune-related adve ...... pilimumab: report of two cases

@en

Neurologic immune-related adve ...... pilimumab: report of two cases

@nl

type

Item

label

Neurologic immune-related adve ...... pilimumab: report of two cases

@en

Neurologic immune-related adve ...... pilimumab: report of two cases

@nl

prefLabel

Neurologic immune-related adve ...... pilimumab: report of two cases

@en

Neurologic immune-related adve ...... pilimumab: report of two cases

@nl

P1476

Neurologic immune-related adve ...... pilimumab: report of two cases

@en

P2093

Alex El-Ali

http://www.w3.org/2001/XMLSchema#string

Christine A Garcia

http://www.w3.org/2001/XMLSchema#string

Jan Drappatz

http://www.w3.org/2001/XMLSchema#string

Lydia C Contis

http://www.w3.org/2001/XMLSchema#string

Tanya J Rath

http://www.w3.org/2001/XMLSchema#string

Vikram Gorantla

http://www.w3.org/2001/XMLSchema#string

P2860

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Toxicity management of immunotherapy for patients with metastatic melanoma

Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Enhancement of antitumor immunity by CTLA-4 blockade

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

P2888

s40425-018-0393-z

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S40425-018-0393-Z

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Diwakar Davar

P577

2018-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106468056

http://www.w3.org/2001/XMLSchema#string

P698

30170622

http://www.w3.org/2001/XMLSchema#string

P921

P932

6117978

http://www.w3.org/2001/XMLSchema#string